Abstract:OATP1B1 and OATP1B3 are two important drug uptake transporters expressed in human hepatocytes. They mediate the uptake of numerous drugs and other compounds and multiple inhibitors have been identified. However, it has also been suggested that these inhibitors may act as substrates for OATPs. Therefore, we wanted to establish the competitive counterflow assay described by Harper and Wright ( Am J Physiol Renal Physiol 2013; 304:F56–67 ) for OATP1B1 and OATP1B3 with the model substrate estradiol‐17β‐glucuronide (E17βG). This assay should allow to identify compounds that are able to exchange for an OATP substrate such as [ 3 H]‐E17βG that was used to preload OATP expressing CHO cells. CHO cells stably expressing either OATP1B1 or OATP1B3 were used and time dependent uptake of 10nM [ 3 H]‐E17βG was determined on 96‐well plates. Uptake reached a steady‐state plateau at 2 hours and addition of unlabeled E17βG to the extracellular medium at this time triggered time and concentration dependent efflux of [ 3 H]‐E17βG from the preloaded cells, indicating that extracellular E17βG exchanged for intracellular [ 3 H]‐E17βG. This assay was then used to test whether several known OATP substrates would also lead to [ 3 H]‐E17βG efflux, indicating that they are exchanged for the intracellular substrate. After preloading the cells with [ 3 H]‐E17βG, addition of known substrates such as E17βG, estrone‐3‐sulfate, bromosulfophthalein, taurocholate, and rifampicin to the extracellular medium indeed resulted in [ 3 H]‐E17βG efflux, confirming that OATP1B1 and OATP1B3 handle their substrates as exchangers. As negative controls we used glucose, glutamic acid, ouabain and metformin which did not result in [ 3 H]‐E17βG efflux. We then began testing known OATP inhibitors to see whether they would trigger [ 3 H]‐E17βG efflux, and thus would be OATP substrates. Among the tested inhibitors, many resulted in [ 3 H]‐E17βG efflux from both OATP1B1 and OATP1B3 expressing CHO cells, and thus seem to be substrates. These included bromocryptine, cyclosporine A, DIDS, indomethacin, ketoconazole, reserpine, and salinomycin. A few, including berberine, erythromycin, gliquidone, nifedipine, and paranitrosaniline seem to be substrates only for OATP1B1. Thus, because the tested substrates do not need to be radiolabeled and the CCF assay can be performed on 96‐well plates, this is a good screening tool to identify OATP inhibitors that are transported substrates. Support or Funding Information This work was supported by the National Institute of Health Grants R01‐GM077335 and P20‐GM103549‐07.

Research on annihilation of cancer cells by glass-ceramics for cancer treatment with external magnetic field. I. Preparation and cytotoxicity.

Studies on Determination and in Vitro Metabolism of Ginkgolides and Bilobalide in Rat Liver Microsomes by Using HPLC-ELSD Method

Determination of urinary and serum pentosidine and its application to elder patients.

Glucose‐6‐phosphate dehydrogenase activity in hyperplastic and neoplastic lesions of the breast. A histochemical study

Absolute Quantification of Cytochrome P450 and Uridinediphosphate Glucuronosyl Transferase Isoforms by Proteomics-based Approach

A Validated Surrogate Analyte UPLC-MS/MS Assay for Quantitation of TUDCA, TCDCA, UDCA, and CDCA in Rat Plasma: Application in a Pharmacokinetic Study of Cultured Bear Bile Powder.

Significant increases in detection capability for assessment of organic anion transporting polypeptide-mediated drug-drug interaction in cynomolgus monkeys by modifying pretreatment of Coproporphyrin I and III, and glycochenodeoxycholate-3-sulfate in plasma

Quantification of 4-Beta-hydroxycholesterol in Human Plasma Using Automated Sample Preparation and LC-ESI-MS/MS Analysis

Development and validation of an LC–MS/MS method to quantify kynurenic acid in human plasma

Independent Component Automatic Clustering and its application on multi-trails imaginary hand movement related EEG

Identification and characterization of endogenous biomarkers for hepatic vectorial transport (OATP1B3-P-gp) function using metabolomics with serum pharmacology

Simultaneous determination of Obeticholic acid and its two major metabolites in human plasma after administration of Obeticholic acid tablets using ultra-high performance liquid chromatography tandem mass spectrometry

High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma.

Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug–Drug Interaction in Healthy Volunteers

Fast and Direct Determination of Catechol-3, 6-Bis(methyleiminodiacetic Acid) Prototype in Beagle Dog Plasma Using Liquid Chromatography Tandem Mass Spectrometry: A Simplified and High Throughput In-Vivo Method for the Metal Chelator.

Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys

An HPLC–MS/MS Method for Quantitation of Gly-MCA in Mouse Plasma: Application to a Pharmacokinetic Study

Development and Validation of Liquid Chromatography-mass Spectrometry Method for the Determination of Intracellular Concentration of Ginkgolide A, B, C, and Bilobalide in Transporter-Expressing Cells

Establishing the Competitive Counterflow Assay for OATP1B1 and OATP1B3

Development and Validation of an LC-MS/MS Method for the Determination of a Novel Thienoquinolin Urea Transporter Inhibitor PU-48 in Rat Plasma and Its Application to a Pharmacokinetic Study.

Gc/Tof-Ms-Based Analytical Method Of Endogenous Metabolites For Mouse Serum